Cargando…

Correction: ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma

Detalles Bibliográficos
Autores principales:	Zhu, Liangsong, Ding, Rong, Yan, Hao, Zhang, Jin, Lin, Zongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046752/ https://www.ncbi.nlm.nih.gov/pubmed/33854032 http://dx.doi.org/10.1038/s41419-021-03678-9

Ejemplares similares

ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma
por: Zhu, Liangsong, et al.
Publicado: (2020)

Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma
por: Zhu, Liangsong, et al.
Publicado: (2019)

ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells
por: Kwon, Ryuk-Jun, et al.
Publicado: (2016)

Correction to: PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

Novel VHL substrate targets SFMBT1 and ZHX2 may be important prognostic predictors in patients with ccRCC
por: Chen, Yufeng, et al.
Publicado: (2021)

Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia
por: Maciel, Natália Ioseph Gladistone, et al.
Publicado: (2021)

ZHX2 in health and disease
por: Li, Na, et al.
Publicado: (2022)

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
por: Diaz-Montero, C Marcela, et al.
Publicado: (2016)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma
por: Nagase, Kei, et al.
Publicado: (2021)

Correction to: Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma
por: Guo, Kai, et al.
Publicado: (2022)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway
por: Wang, Jun, et al.
Publicado: (2020)

Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
por: Arafeh, Rand, et al.
Publicado: (2019)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

Acute Acalculous Cholecystitis in Patients With Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Report of Two Cases
por: Furubayashi, Nobuki, et al.
Publicado: (2014)

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
por: Peng, Qiang, et al.
Publicado: (2019)

TFE3‐PD‐L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
por: Guo, Xudong, et al.
Publicado: (2020)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
por: Song, Zhengshuai, et al.
Publicado: (2020)

MEK5/ERK5 Signaling Modulates Endothelial Cell Migration and Focal Contact Turnover
por: Spiering, Désirée, et al.
Publicado: (2009)

PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway
por: Sun, Jinmin, et al.
Publicado: (2021)

Correction: Continuing a cancer treatment despite tumor growth may be valuable: Sunitinib in renal cell carcinoma as example
Publicado: (2014)

Sunitinib for advanced renal cell cancer
por: Coppin, Chris
Publicado: (2008)

Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)

Zhx2 maintains islet β-cell mass and function by transcriptionally regulating Pax6
por: Ding, Lu, et al.
Publicado: (2023)

Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway
por: Gao, Yongqian, et al.
Publicado: (2016)

Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells
por: Liu, Yi Lun, et al.
Publicado: (2014)

Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway
por: Qian, Jun, et al.
Publicado: (2020)

AB014. Sunitinib affects autophagy and apoptosis via regulation of glycolysis in renal cell carcinoma cells
por: Xi, Zhijun
Publicado: (2016)

Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway
por: Maddahi, Aida, et al.
Publicado: (2011)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021)

miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma
por: Park, Sang Eun, et al.
Publicado: (2022)

Correction: Amphiregulin enhances alpha6beta1 integrin expression and cell motility in human chondrosarcoma cells through Ras/Raf/MEK/ERK/AP-1 pathway
por: Chen, Jui-Chieh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vciu5nrkcik9esdcf2ojuct696